Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIXNASDAQ:BRNSNASDAQ:MDXHNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$1.74+0.6%$2.50$1.52▼$75.80$4.29M-5.4284,302 shs16,657 shsBRNSBarinthus Biotherapeutics$0.76-5.6%$1.01$0.76▼$4.16$30.57M-0.833,736 shs47,329 shsMDXHMDxHealth$1.50+3.1%$1.72$1.35▼$3.50$70.93M1.3783,049 shs66,521 shsSYRESpyre Therapeutics$15.49+1.2%$20.19$14.88▼$40.84$933.38M2.98559,979 shs586,262 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical+0.58%-6.95%-26.89%-48.37%-97.09%BRNSBarinthus Biotherapeutics-5.55%-28.30%-21.65%-38.71%-67.93%MDXHMDxHealth+3.09%-0.67%-12.28%-34.78%-48.81%SYRESpyre Therapeutics+1.24%-8.99%-13.66%-35.05%-54.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMIXAutonomix Medical3.5208 of 5 stars3.55.00.00.02.81.71.3BRNSBarinthus Biotherapeutics2.02 of 5 stars3.53.00.00.00.80.01.3MDXHMDxHealth2.3353 of 5 stars3.53.00.00.01.90.01.3SYRESpyre Therapeutics2.0041 of 5 stars3.60.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 3.00Buy$28.001,509.20% UpsideBRNSBarinthus Biotherapeutics 3.00Buy$5.17579.82% UpsideMDXHMDxHealth 3.00Buy$6.50333.33% UpsideSYRESpyre Therapeutics 3.13Buy$50.33224.94% UpsideCurrent Analyst Ratings BreakdownLatest AMIX, BRNS, SYRE, and MDXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025BRNSBarinthus BiotherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2025BRNSBarinthus BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.002/18/2025SYRESpyre TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/13/2025BRNSBarinthus BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.001/13/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$8.12 per shareN/ABRNSBarinthus Biotherapeutics$14.97M2.04N/AN/A$4.85 per share0.16MDXHMDxHealth$90.05M0.79N/AN/A$4.62 per share0.32SYRESpyre Therapeutics$890K1,048.74N/AN/A($0.22) per share-70.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$15.43M-$12.93N/AN/AN/AN/A-212.48%-161.13%N/ABRNSBarinthus Biotherapeutics-$73.35M-$1.55N/AN/AN/AN/A-34.26%-29.30%5/12/2025 (Estimated)MDXHMDxHealth-$43.10M-$1.27N/AN/AN/A-49.52%-1,077.84%-28.82%5/7/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$4.23N/AN/AN/AN/A-210.01%-44.40%5/8/2025 (Estimated)Latest AMIX, BRNS, SYRE, and MDXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024BRNSBarinthus Biotherapeutics-$0.50-$0.51-$0.01-$0.51N/A$14.97 million2/27/2025Q4 2024SYRESpyre Therapeutics-$0.89-$0.81+$0.08-$0.81$2.10 millionN/A2/26/2025Q4 2024MDXHMDxHealth-$0.21-$0.14+$0.07-$0.14$22.67 million$24.74 million2/13/2025Q3 2025AMIXAutonomix MedicalN/A-$1.46N/A-$1.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A5.315.31BRNSBarinthus BiotherapeuticsN/A8.938.93MDXHMDxHealth3.141.541.45SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%BRNSBarinthus Biotherapeutics25.20%MDXHMDxHealthN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical32.40%BRNSBarinthus Biotherapeutics8.00%MDXHMDxHealth1.70%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical12.46 million1.67 millionN/ABRNSBarinthus Biotherapeutics10740.23 million37.01 millionN/AMDXHMDxHealth30047.29 million46.48 millionNot OptionableSYRESpyre Therapeutics10060.26 million48.24 millionOptionableAMIX, BRNS, SYRE, and MDXH HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Buys 266,418 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 2 at 4:30 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Time to Sell?April 2 at 4:11 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - Here's What HappenedApril 1 at 3:31 PM | marketbeat.comSwiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 30, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's WhyMarch 29, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 28, 2025 | finanznachrichten.deSpyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Still a Buy?March 28, 2025 | marketbeat.comNatixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 28, 2025 | marketbeat.comAptorum Group (NASDAQ:APM) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head SurveyMarch 28, 2025 | americanbankingnews.comSpyre Therapeutics says first patient dosed in Phase 1 trial of SPY003March 27, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's WhyMarch 27, 2025 | marketbeat.comSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 27, 2025 | prnewswire.comEFG Asset Management North America Corp. Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 27, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - Here's What HappenedMarch 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 254,222 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 23, 2025 | marketbeat.comCommit To Buy Spyre Therapeutics At $12.50, Earn 13.5% Annualized Using OptionsMarch 21, 2025 | nasdaq.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wolfe ResearchMarch 19, 2025 | marketbeat.comSpyre Therapeutics initiated with an Outperform at Wolfe ResearchMarch 18, 2025 | markets.businessinsider.comVictory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, BRNS, SYRE, and MDXH Company DescriptionsAutonomix Medical NASDAQ:AMIX$1.74 +0.01 (+0.58%) Closing price 04/2/2025 03:59 PM EasternExtended Trading$1.69 -0.05 (-2.82%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Barinthus Biotherapeutics NASDAQ:BRNS$0.76 -0.04 (-5.55%) Closing price 04/2/2025 03:59 PM EasternExtended Trading$0.76 +0.00 (+0.26%) As of 04/2/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.MDxHealth NASDAQ:MDXH$1.50 +0.05 (+3.09%) As of 04/2/2025 04:00 PM EasternMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Spyre Therapeutics NASDAQ:SYRE$15.49 +0.19 (+1.24%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$14.88 -0.61 (-3.93%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
